Company Information

    Celularity was founded on July 2017. The company is based in Warren, NJ, USA . The number of employees in Celularity is less than 250. Celularity is a clinical-stage cell therapeutics company delivering transformative allogeneic cellular therapies.
      If you are the founder or part of the founding team, please tell the world your story


          Funding & investors

          Celularity has received 2 rounds of venture funding. The total funding amount is around $290M.

            Similar Companies [beta]

              Venture Categories

                Active Venture Investors




                  Venture Competitors

                    News

                        Celularity - Blog

                          • Celularity To Be Added To The Russell 3000® Index And The Small-Cap Russell 2000®

                          • Today we announced we are set to join the broad-market Russell 3000® and the Russell 2000® Indexes at the conclusion of the 2022 Russell indexes annual reconstitution, effective after the U.S. market opens on June 27, 2022 according to a preliminary list of additions posted June 3, 2022.The post Celularity To Be Added To The Russell 3000® Index And The Small-Cap Russell 2000® appeared first on Celularity.
                          • Celularity Appoints Industry Leader Diane Parks to its Board of Directors

                          • Today we announced the appointment of Diane Parks to its Board of Directors. Ms. Parks, an executive with deep experience in the commercialization of novel immuno-oncology therapies, has led the successful launch of numerous hematology and cancer therapies at large pharmaceutical and biotech companies, including Kite Pharma, Inc. (now part of Gilead Sciences, Inc.), Amgen Inc., and Genentech, Inc. (now part of Roche Holdings, Inc.).The post Celularity Appoints Industry Leader Diane Parks to its Board of Directors appeared first on Celularity.
                          • Celularity Inc. Announces $30 Million Private Placement Priced At-The-Market Under Nasdaq Rules

                          • Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale of 4,054,055 shares of its common stock at a purchase price of $7.40 per share and warrants to purchase 4,054,055 shares of its common stock at an exercise price of $8.25 per share (together the “Securities”) in a private placement priced at-the-market under Nasdaq rules, resulting in total gross proceeds of approximately $30.0 million before deducting placement agent commissions and other estimated offering expenses. The warrants will be exercisable immediately after the date of issuance and will expire five years following the initial issuance date. The closing of the offering and sale of the Securities is expected to occur on or about May 20, 2022, subject to the satisfaction of customary closing conditions. The post Celularity Inc. Announces $30 Million Private Placement Priced At-The-Market Under Nasdaq Rules appeared first on Celularity.
                          • Celularity Reports First Quarter 2022 Financial Results and Provides Corporate Update

                          • Today we announced financial results for the first quarter ended March 31, 2022, and provided a corporate update.The post Celularity Reports First Quarter 2022 Financial Results and Provides Corporate Update appeared first on Celularity.
                          • Celularity Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

                          • Today we reported fourth quarter and full year 2021 financial results and a corporate update.The post Celularity Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update appeared first on Celularity.
                          • Transcript: Oppenheimer 32nd Annual Healthcare Conference

                          • The post Transcript: Oppenheimer 32nd Annual Healthcare Conference appeared first on Celularity.

                          Share:     facebook    twitter    linkedin    reddit    email

                            Ventures Media is one of the largest startup and venture capital communities for startup and venture capital funding information and analysis.

                            Leave a Reply

                            Your email address will not be published. Required fields are marked *